AstraZeneca

AZN

Market cap $287B

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

AZN and MRK boast major oncology strengths and expanding pipelines amid shifting market dynamics in this pharma matchup.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

The IRA from 2022 allows the CMS to negotiate prices for a number of drugs each year for patients in Medicare. Late Tuesday, the agency announced newly negotiated prices for 15 blockbuster drugs from 2027, including Novo Nordisk's mega bestseller Ozempic which will see a 71% discount to its list price.

Hong Kong-based Harbour BioMed announced on Sunday an update and advancement of its global strategic collaboration with AstraZeneca Plc (NASDAQ: AZN), initially established in March 2025.

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI , Nov. 23, 2025 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics for immunology and oncology, today announced an update and advancement of its global strategic collaboration with AstraZeneca, originally established in March 2025.

AstraZeneca CEO Pascal Soriot joins 'Mad Money' host Jim Cramer to talk manufacturing expansion, growth plans, next-gen therapies, and more.

The pharmaceutical giant is plowing billions of dollars into expanding its drug-making capacity. It has ambitious plans for two facilities in Maryland.

AstraZeneca said on Friday it will invest $2 billion to expand its manufacturing footprint in Maryland as part of its previously announced $50 billion plan to expand manufacturing and research capabilities in the U.S. by 2030.

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announces plans to invest $2 billion to expand its long-standing manufacturing footprint in Maryland. This includes a significant expansion of its flagship biologics manufacturing facility in Frederick and construction of a new state-of-the-art facility in Gaithersburg for the development and clinical supply of innovative molecules to be used in clinical trials. The investment will support 2,600 jobs across the two sites in the state includin.